API Testing Requirements to Support the EI Risk Assessment
Elisabeth CorbettAssociate Director, GRS-CMC, Bristol-Myers Squibb
November 9, 2016
AgendaBackground Review of ICH Q3D Risk Assessment Principles Challenges associated with API implementation
The API Risk Assessment (RA) for EI Constructing the initial assessment Conducting testing and assessing data Considering the additional RA factors
– Starting materials– Equipment and Container Closure
Implementation across a Portfolio Driving consistency and Documenting Strategy
2
BackgroundReview of ICH Q3D Risk Assessment Principles
What is a Risk Assessment? Per ICH Q3D:
– “A systematic process of organizing information to support a risk decision to be made within a risk management process.”
Per ICH Q9:– “Three fundamental questions are often helpful:
1. What might go wrong? 2. What is the likelihood (probability) it will go wrong? 3. What are the consequences (severity)?
3
BackgroundReview of ICH Q3D Risk Assessment Principles
Components of the ICH Q3D Risk Assessment: The Fishbone Diagram:
– API and Excipients considered most likely sources for EI contamination for most dosage forms
– Diagram starts with API, but there are components that need to be assessed for contribution to overall risk
4
Starting Materials and Reagents
Equipment Exposure
Container Closure
BackgroundChallenges Associated with Implementation
Implementation: If the risk assessment is:
– “A systematic process of organizing information to support a risk decision to be made within a risk management process.”
If the assessment starts with API:
5
What kind and how muchinformation is considered
adequate?
Starting Materials and Reagents
Equipment Exposure
Container Closure
How much and what kind of information is neededto assess these factors?
6
When? Preparation should begin prior to definition of acceptance
criteria for drug substance intended for clinical studies
How?1- Analysis of the Synthetic Route:Assess route for intentionally added EIs and EIs known to be introduced by starting materials
2- Outline of Testing Strategy for Development Lots:Route of Administration
Class 1
Class 2A
Class2B
Class3
Intentionally Added
Oral x x xParenteral x x x x
The API Risk AssessmentConstructing the Initial Risk Assessment
7
Conducting Testing Collection of general (non-intentional metal) data to
support the risk assessment should begin in development with qualified methods
– “Should possess characteristics… such the manufacturer can be reasonably certain… the measurements can be relied upon to decided whether to include routine testing… in the control strategy”1
Collection of data to support removal of intentionally added metals to acceptable levels (e.g. < 30% of PDE remaining) should begin in development using specific method
– Specification may be needed for clinical supplies
The API Risk AssessmentConducting Testing and Collating Data
1 Elemental Impurities in Drug Products, DRAFT Guidance for Industry, FDA, June 2016.
8
Assessing Data Determine Control Strategy from LTSS to the Marketing
Application– Continue monitoring as per the development plan – Assess development and pilot data
• Determine whether process control or routine testing is appropriate
The API Risk AssessmentConducting Testing and Assessing Data
Minimum 3 commercial batches OR 6 pilot
batches
Demonstrate the absence of EI:“Show with convincing evidence that it is purged to a level which is consistently below 30% of the calculated concentration limit based on intended route of administration”
1 Implementation of ICH Q3D in the Certification Procedure, EDQM, August 2016.
9
Starting Materials Are EIs introduced via SM synthetic route?
– No: Screen 3 lots of vendor material to demonstrate absence of EI
Is there a supplier specification already in place for intentional EIs?
– No: Calculate max allowable to remain below threshold in API and determine whether a spec is needed based on screening of 3 vendor lots
– Yes: Calculate max contribution in API at spec and determine if adequate or if an internal or lower vendor spec is needed
Could other metals serve as alternative to the intentional EI?
– Yes: Screen lots for these EIs in addition to that of current route
The API Risk AssessmentConsidering the Additional RA Factors
10
The API Risk AssessmentConsidering the Additional RA FactorsStarting Materials (cont.’) What if the vendor makes changes?
– Quality agreements and change control address- not necessarily more testing!
What if the vendor introduces new EIs into facility in other syntheses?
– Qualified suppliers should be assessed as having adequate GMPs and cleaning procedures in place
1. What might go wrong? 2. What is the likelihood
it will go wrong? 3. What are the consequences?
11
Equipment and Container Closure Equipment- Low Risk
– Screening for class 1 elements and additional known EIs from stainless (Ni, V and Co) throughout development (see ICH Q3D Case Study 1A)
– Combination of screening information and quality system procedures in place (see ICH Q3D Case Study 2)
– Biologics may need to consider possible EI contribution more thoroughly
Container Closure- No Risk– Solid API offers no mechanism for transfer of EI from
storage container
The API Risk AssessmentConsidering the Additional RA Factors
Implementation Across a PortfolioDriving Consistency and Documenting Strategy
12
Ideal State Harmonized approach to implementation across teams Risk assessments developed early in program Consistent approach with suppliers
Getting to the Ideal State… Centralized committee charged with:
Providing training and background on the guideline
Working with individual development program teams to :
Construct initial EI strategy/approach for API
Assess the EI risk associated with raw materials and intermediates
Implement the appropriate testing strategy with suppliers
Provide guidance/responses in the event of regulatory questions